Partnerships Target Drug Conjugates | Chemical & Engineering News
Volume 92 Issue 26 | p. 14 | Concentrates
Issue Date: June 30, 2014

Partnerships Target Drug Conjugates

Department: Business
Keywords: antibody-drug conjugates, ADCs

Sorrento Therapeutics and Morphotek, a subsidiary of Japan’s Eisai, will collaborate on generating antibody-drug conjugates (ADCs) for cancer. Morphotek antibodies will be combined with chemotherapeutic agents using Sorrento conjugation chemistry and linkers. Sorrento could receive up to $50 million. Similarly, Mersana Therapeutics will work with Merck Serono to develop ADCs for oncology targets. The partners will use Mersana’s biodegradable polymer linker, or Fleximer technology, to generate a range of ADCs from several cytotoxic agents conjugated to Merck antibodies.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment